Paul Chew

Thoughtful frustrated woman sitting at table near laptop

Filling the Tech Gap in Metastatic Breast Cancer Clinical Trials

According to the American Cancer Society (ACS), a woman living in the United States has a 1 in 8 chance of developing breast cancer, the second-leading cause of cancer death in women (behind only lung cancer). Despite advances in treatment, about 30% of women initially diagnosed with early-stage breast cancer will have a recurrence or experience metastatic disease.[i] Moreover, while…

img

KOLs: An Endangered Buzzword

The term, “key opinion leader” (supported by its well-known acronym KOL) is one of the industry’s most common buzzwords, and for good reason. Physician KOLs have always influenced treatment guidelines and practice behaviors. They have traditionally exerted their influence through research and publication on drug safety and efficacy, which, while still valuable, must now share the stage with other important…

img

Smarter Trials Equal Faster Cures

In this era of “big data,” when we all have access to more data than ever before, it’s tempting to take a ‘DIY’ approach to clinical research. However, as search engines become increasingly sophisticated, many data sources commonly used to support clinical trial design lack such dynamism. For example, whereas many clinical trial planners rely on sources like clinicaltrials.gov, which…

img

“PROactively” Pursuing mHealth in Clinical Trials

The concept of patient-reported outcomes (PROs) in #clinicaltrials is certainly not new, but advances in mobile tech are helping to position PROs as a game-changing factor. In just the past few years, a whole new mHealth industry has arisen, spurring the development and adoption of wearable and sensor-based devices loaded with applications that monitor and transmit patient data in real…